Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price of $5.25 per share, before underwriting discounts. The offering is expected to close on or about January 22, 2018, subject to customary closing conditions. In addition, Arrowhead has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less the underwriting discount. Jefferies LLC and Barclays Capital Inc. are acting as bookrunning managers for the offering, Cantor Fitzgerald & Co. is acting as passive joint bookrunner for the offering and Chardan and B. Riley FBR, Inc. are acting as co-managers for the offering.

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock

Pasadena, CA | Posted on January 18th, 2018

Gross offering proceeds will be approximately $52.5 million, before deducting underwriting discounts and commissions and offering expenses. Arrowhead intends to use the net proceeds from this offering for general corporate purposes, including working capital, capital expenditures, research and development expenditures and clinical trial expenditures. A portion of the net proceeds may also be used for the acquisition of complementary businesses, products and technologies, or for other strategic purposes.

A shelf registration statement on Form S-3 (File No. 333-214315) relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. When available, copies of the final prospectus supplement may also be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at or from Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-888-603-5847, or email: .

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding our expectations with respect to our proposed public offering. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, without limitation, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K, and other SEC filings discuss some of the important risk factors that may affect our ability to achieve the anticipated results, as well as our business, results of operations and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements. Additionally, Arrowhead disclaims any intent to update these forward-looking statements to reflect subsequent developments.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Machine learning speeds modeling of experiments aimed at capturing fusion energy on Earth May 17th, 2019

Manipulating atoms one at a time with an electron beam: New method could be useful for building quantum sensors and computers May 17th, 2019

New surface treatment could improve refrigeration efficiency: A slippery surface for liquids with very low surface tension promotes droplet formation, facilitating heat transfer May 17th, 2019

Generating high-quality single photons for quantum computing: New dual-cavity design emits more single photons that can carry quantum information at room temperature May 17th, 2019

Possible Futures

Machine learning speeds modeling of experiments aimed at capturing fusion energy on Earth May 17th, 2019

Manipulating atoms one at a time with an electron beam: New method could be useful for building quantum sensors and computers May 17th, 2019

New surface treatment could improve refrigeration efficiency: A slippery surface for liquids with very low surface tension promotes droplet formation, facilitating heat transfer May 17th, 2019

Generating high-quality single photons for quantum computing: New dual-cavity design emits more single photons that can carry quantum information at room temperature May 17th, 2019

Investments/IPO's/Splits

Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences May 3rd, 2019

Nanometrics Announces Participation in Upcoming Investor Conferences May 3rd, 2019

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.76 as of March 31, 2019; an Increase of 4.5% From December 31, 2018 May 1st, 2019

180 Degree Capital Corp. to Report First Quarter 2019 Financial Results on Wednesday, May 1, 2019 and to Host a Conference Call on Thursday, May 2, 2019 April 26th, 2019

Nanomedicine

Better microring sensors for optical applications May 10th, 2019

New efficient way to engineer nanostructures mimicking natural immune response complexes: Novel method to engineer large multi-antibody-like nanostructures using DNA nanotechnology; the results demonstrate the potential for assembly of multiple proteins and also other materials t May 10th, 2019

Nanotubes enable travel of Huntington's protein: Rhes protein makes its own road to convey disease drivers May 10th, 2019

A cautionary tale for researchers working on selective drug delivery May 9th, 2019

Announcements

Machine learning speeds modeling of experiments aimed at capturing fusion energy on Earth May 17th, 2019

Manipulating atoms one at a time with an electron beam: New method could be useful for building quantum sensors and computers May 17th, 2019

New surface treatment could improve refrigeration efficiency: A slippery surface for liquids with very low surface tension promotes droplet formation, facilitating heat transfer May 17th, 2019

Generating high-quality single photons for quantum computing: New dual-cavity design emits more single photons that can carry quantum information at room temperature May 17th, 2019

Nanobiotechnology

New efficient way to engineer nanostructures mimicking natural immune response complexes: Novel method to engineer large multi-antibody-like nanostructures using DNA nanotechnology; the results demonstrate the potential for assembly of multiple proteins and also other materials t May 10th, 2019

Nanotubes enable travel of Huntington's protein: Rhes protein makes its own road to convey disease drivers May 10th, 2019

A cautionary tale for researchers working on selective drug delivery May 9th, 2019

Vaccine design can dramatically improve cancer immunotherapies: Effectiveness depends on molecular architecture and 3D presentation of components May 6th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project